Targeting the Warburg effect in hematological malignancies: From PET to therapy

Mala Shanmugam, Samuel K. McBrayer, Steven T. Rosen

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Purpose of review: To highlight key studies providing rationale for and utility in targeting glycolysis for the treatment of hematological malignancies. Recent findings: Several therapeutic strategies are capitalizing on the diagnostic utility of 18fluorodeoxyglucose positron emission tomography that relies on increased glycolysis and glucose utilization in tumor cells. Although aerobic glycolysis was initially proposed by Warburg to be due to mitochondrial impairment, recent studies have shown a preferential switch to glycolysis in tumor cells with functional mitochondria. Increased glucose consumption can be advantageous for a tumor cell through stimulation of cellular biosynthetic, energetic, and pro-survival pathways. We now have a greater appreciation for the utilization of glucose in specific metabolic pathways that in some aspects can be complemented with other nutrients such as glutamine. Targeting glucose consumption for the treatment of hematological malignancies seems to be a promising field that will require characterization of tumor cell specific targets to inhibit glucose uptake and/or glycolysis. It is imperative to further our understanding of the tumor cell metabolome to target cellular bioenergetics in the treatment of cancer. Summary Targeting the glycolytic pathway for the treatment of hematological malignancies has sufficient rationale given the utility of 18fluoro-deoxyglucose positron emission tomography in diagnostic imaging. Further research is required in developing tumor cell specific therapeutics.

Original languageEnglish (US)
Pages (from-to)531-536
Number of pages6
JournalCurrent Opinion in Oncology
Volume21
Issue number6
DOIs
StatePublished - Nov 1 2009
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Glycolysis
Glucose
Neoplasms
Positron-Emission Tomography
Therapeutics
Metabolome
Deoxyglucose
Diagnostic Imaging
Metabolic Networks and Pathways
Glutamine
Energy Metabolism
Mitochondria
Food
Research

Keywords

  • Glucose
  • Glycolysis
  • Hematologic malignancies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the Warburg effect in hematological malignancies : From PET to therapy. / Shanmugam, Mala; McBrayer, Samuel K.; Rosen, Steven T.

In: Current Opinion in Oncology, Vol. 21, No. 6, 01.11.2009, p. 531-536.

Research output: Contribution to journalReview article

@article{359d335d7d4143e4b298fb04f63ec2a1,
title = "Targeting the Warburg effect in hematological malignancies: From PET to therapy",
abstract = "Purpose of review: To highlight key studies providing rationale for and utility in targeting glycolysis for the treatment of hematological malignancies. Recent findings: Several therapeutic strategies are capitalizing on the diagnostic utility of 18fluorodeoxyglucose positron emission tomography that relies on increased glycolysis and glucose utilization in tumor cells. Although aerobic glycolysis was initially proposed by Warburg to be due to mitochondrial impairment, recent studies have shown a preferential switch to glycolysis in tumor cells with functional mitochondria. Increased glucose consumption can be advantageous for a tumor cell through stimulation of cellular biosynthetic, energetic, and pro-survival pathways. We now have a greater appreciation for the utilization of glucose in specific metabolic pathways that in some aspects can be complemented with other nutrients such as glutamine. Targeting glucose consumption for the treatment of hematological malignancies seems to be a promising field that will require characterization of tumor cell specific targets to inhibit glucose uptake and/or glycolysis. It is imperative to further our understanding of the tumor cell metabolome to target cellular bioenergetics in the treatment of cancer. Summary Targeting the glycolytic pathway for the treatment of hematological malignancies has sufficient rationale given the utility of 18fluoro-deoxyglucose positron emission tomography in diagnostic imaging. Further research is required in developing tumor cell specific therapeutics.",
keywords = "Glucose, Glycolysis, Hematologic malignancies",
author = "Mala Shanmugam and McBrayer, {Samuel K.} and Rosen, {Steven T.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1097/CCO.0b013e32832f57ec",
language = "English (US)",
volume = "21",
pages = "531--536",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Targeting the Warburg effect in hematological malignancies

T2 - From PET to therapy

AU - Shanmugam, Mala

AU - McBrayer, Samuel K.

AU - Rosen, Steven T.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Purpose of review: To highlight key studies providing rationale for and utility in targeting glycolysis for the treatment of hematological malignancies. Recent findings: Several therapeutic strategies are capitalizing on the diagnostic utility of 18fluorodeoxyglucose positron emission tomography that relies on increased glycolysis and glucose utilization in tumor cells. Although aerobic glycolysis was initially proposed by Warburg to be due to mitochondrial impairment, recent studies have shown a preferential switch to glycolysis in tumor cells with functional mitochondria. Increased glucose consumption can be advantageous for a tumor cell through stimulation of cellular biosynthetic, energetic, and pro-survival pathways. We now have a greater appreciation for the utilization of glucose in specific metabolic pathways that in some aspects can be complemented with other nutrients such as glutamine. Targeting glucose consumption for the treatment of hematological malignancies seems to be a promising field that will require characterization of tumor cell specific targets to inhibit glucose uptake and/or glycolysis. It is imperative to further our understanding of the tumor cell metabolome to target cellular bioenergetics in the treatment of cancer. Summary Targeting the glycolytic pathway for the treatment of hematological malignancies has sufficient rationale given the utility of 18fluoro-deoxyglucose positron emission tomography in diagnostic imaging. Further research is required in developing tumor cell specific therapeutics.

AB - Purpose of review: To highlight key studies providing rationale for and utility in targeting glycolysis for the treatment of hematological malignancies. Recent findings: Several therapeutic strategies are capitalizing on the diagnostic utility of 18fluorodeoxyglucose positron emission tomography that relies on increased glycolysis and glucose utilization in tumor cells. Although aerobic glycolysis was initially proposed by Warburg to be due to mitochondrial impairment, recent studies have shown a preferential switch to glycolysis in tumor cells with functional mitochondria. Increased glucose consumption can be advantageous for a tumor cell through stimulation of cellular biosynthetic, energetic, and pro-survival pathways. We now have a greater appreciation for the utilization of glucose in specific metabolic pathways that in some aspects can be complemented with other nutrients such as glutamine. Targeting glucose consumption for the treatment of hematological malignancies seems to be a promising field that will require characterization of tumor cell specific targets to inhibit glucose uptake and/or glycolysis. It is imperative to further our understanding of the tumor cell metabolome to target cellular bioenergetics in the treatment of cancer. Summary Targeting the glycolytic pathway for the treatment of hematological malignancies has sufficient rationale given the utility of 18fluoro-deoxyglucose positron emission tomography in diagnostic imaging. Further research is required in developing tumor cell specific therapeutics.

KW - Glucose

KW - Glycolysis

KW - Hematologic malignancies

UR - http://www.scopus.com/inward/record.url?scp=74049160403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049160403&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e32832f57ec

DO - 10.1097/CCO.0b013e32832f57ec

M3 - Review article

C2 - 19587591

AN - SCOPUS:74049160403

VL - 21

SP - 531

EP - 536

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -